More than two decades ago a scientific team led by Professor Claude Wischik, a board-certified psychiatrist and holder of a Chair in Mental Health at the University of Aberdeen, pioneered the early-stage research into tau aggregation inhibitors (TAIs) to slow and halt the progression of Alzheimer’s disease and similar neurodegenerative conditions. The results of this foundational research showed promise and TauRx was founded to continue the work towards the development of an effective treatment for the disease. The company remains closely linked to the University of Aberdeen to this day and its strong research capability has been built through long-term cooperative relationships with multiple academic institutions around the world.
Having pioneered a new pathway to treating Alzheimer’s disease, TauRx conducted a large Phase 2 clinical trial involving 321 patients with mild and moderate Alzheimer’s and using the company’s first-generation TAI, rember®. The successful results of the study were presented in 2008 and showed that the rate of Alzheimer’s progression in treated subjects was reduced by 90% over a 2-year period. These findings supported the progression of the project into an initial Phase 3 clinical trial programme completed in 2016 using the company’s second generation TAI, LMTX®. This programme involved over 1,900 patients and comprised three separate trials: two in Alzheimer's disease and one in the rare neurodegenerative disorder, behavioural variant frontotemporal dementia. For more information on the Phase 3 trials, please follow this link.
Since its inception, TauRx has raised almost US$700m to fund its research and development activity. Of this, US$112m was raised in 2012 through a strategic investment from the Genting Berhad group to initiate the Phase 3 clinical trials with a further US$320m raised from new and existing investors during 2013-2017 to support completion of that programme and the initiation of the current Lucidity study. This has recently been supplemented by US$100m committed by an existing shareholder.